Notoginsenoside R1 reduces blood pressure in spontaneously hypertensive rats through a long non-coding RNA AK094457

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 3, 2015, Pages 2700-2709

  Yang, Ying ^a   Xi, Peng ^a   Xie, Yuan ^a   Zhao, Cuimei ^a   Xu, Jiahong ^a   Jiang, Jinfa ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Bioinformatics analysis; Long non coding RNA AK094457; Nitric oxide synthase (iNOS); Notoginsenoside R1 (NR1); Spontaneously hypertensive rats

Indexed keywords

AK094457 LONG NONCODING RNA, RAT; ANTIHYPERTENSIVE AGENT; GINSENOSIDE; INDUCIBLE NITRIC OXIDE SYNTHASE; LONG UNTRANSLATED RNA; NITRIC OXIDE; NOS2 PROTEIN, RAT; NOTOGINSENOSIDE R1;

ANIMAL; AORTA; BIOLOGY; BLOOD PRESSURE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETIC TRANSFECTION; GENETICS; HYPERTENSION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SPONTANEOUSLY HYPERTENSIVE RAT; TIME FACTOR; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GINSENOSIDES; HYPERTENSION; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; RATS, INBRED SHR; RATS, INBRED WKY; RNA INTERFERENCE; RNA, LONG NONCODING; TIME FACTORS; TRANSFECTION;

EID: 84933034225     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Panza JA, Quyyumi AA, Brush JE Jr and Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
2. Hermann M, Flammer A and Luscher TF. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006; 8: 17-29.
3. Gillis CN. Panax ginseng pharmacology: a nitric oxide link? Biochem Pharmacol 1997; 54: 1-8.
4. Sun HX, Pan HJ and Pan YJ. Haemolytic activities and immunologic adjuvant effect of Panax notoginseng saponins. Acta Pharmacol Sin 2003; 24: 1150-1154.
5. Ng TB. Pharmacological activity of sanchi ginseng (Panax notoginseng). J Pharm Pharmacol 2006; 58: 1007-1019.
6. Dong TT, Cui XM, Song ZH, Zhao KJ, Ji ZN, Lo CK and Tsim KW. Chemical assessment of roots of Panax notoginseng in China: regional and seasonal variations in its active constituents. J Agric Food Chem 2003; 51: 4617-4623.
7. Yoshikawa M, Murakami T, Ueno T, Yashiro K, Hirokawa N, Murakami N, Yamahara J, Mat-suda H, Saijoh R and Tanaka O. Bioactive saponins and glycosides. VIII. Notoginseng (1): new dammarane-type triterpene oligoglycosides, notoginsenosides-A, -B, -C, and -D, from the dried root of Panax notoginseng (Burk.) F.H. Chen. Chem Pharm Bull (Tokyo) 1997; 45: 1039-1045.
8. Qi LW, Wang CZ and Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat Prod Rep 2011; 28: 467-495.
9. Choi KT. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 2008; 29: 1109-1118.
10. Huu Tung N, Uto T, Morinaga O, Kim YH and Shoyama Y. Pharmacological effects of ginseng on liver functions and diseases: a minireview. Evid Based Complement Alternat Med 2012; 2012: 173297.
11. Xia ZY, Liu XY, Zhan LY, He YH, Luo T and Xia Z. Ginsenosides compound (shen-fu) attenuates gastrointestinal injury and inhibits inflammatory response after cardiopulmonary bypass in patients with congenital heart disease. J Th-orac Cardiovasc Surg 2005; 130: 258-264.
12. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, Li SH, Lian XM and Tang Z. Panax notoginseng saponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin Exp Pharmacol Physiol 2008; 35: 1238-1244.
13. Hofseth LJ and Wargovich MJ. Inflammation, cancer, and targets of ginseng. J Nutr 2007; 137: 183S-185S.
14. Watson T, Goon PK and Lip GY. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in hypertension. Antioxid Redox Signal 2008; 10: 1079-1088.
15. Vaziri ND and Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006; 2: 582-593.
16. Sandrim VC, Yugar-Toledo JC, Desta Z, Flock-Hart DA, Moreno H Jr and Tanus-Santos JE. Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy. J Hypertens 2006; 24: 2393-2397.
17. Yugar-Toledo JC, Ferreira-Melo SE, Consolim-Colombo FM, Irigoyen MC, Coelho OR and Mo-Reno H Jr. Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 2007; 16: 315-321.
18. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA and Cannon RO 3rd. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91: 1732-1738.
19. Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P and Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
20. Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H and Kajiyama G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25: 898-902.
21. Schonrock N, Harvey RP and Mattick JS. Long noncoding RNAs in cardiac development and pathophysiology. Circ Res 2012; 111: 1349-1362.
22. Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA and Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 2014; 114: 1389-1397.
23. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ and Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science 2004; 306: 1190-1194.
24. Heggermont WA and Heymans S. MicroRNAs are involved in end-organ damage during hypertension. Hypertension 2012; 60: 1088-1093.
25. Liang M, Liu Y, Mladinov D, Cowley AW Jr, Trivedi H, Fang Y, Xu X, Ding X and Tian Z. MicroRNA: a new frontier in kidney and blood pressure research. Am J Physiol Renal Physiol 2009; 297: F553-558.
26. Sung J, Han KH, Zo JH, Park HJ, Kim CH and Oh BH. Effects of red ginseng upon vascular endothelial function in patients with essential hypertension. Am J Chin Med 2000; 28: 205-216.
27. Kim CS, Park JB, Kim KJ, Chang SJ, Ryoo SW and Jeon BH. Effect of Korea red ginseng on cerebral blood flow and superoxide production. Acta Pharmacol Sin 2002; 23: 1152-1156.
28. Jeon BH, Kim CS, Park KS, Lee JW, Park JB, Kim KJ, Kim SH, Chang SJ and Nam KY. Effect of Korea red ginseng on the blood pressure in conscious hypertensive rats. Gen Pharmacol 2000; 35: 135-141.
29. Han KH, Choe SC, Kim HS, Sohn DW, Nam KY, Oh BH, Lee MM, Park YB, Choi YS, Seo JD and Lee YW. Effect of red ginseng on blood pressure in patients with essential hypertension and white coat hypertension. Am J Chin Med 1998; 26: 199-209.
30. Leung KW, Pon YL, Wong RN and Wong AS. Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cells. J Biol Chem 2006; 281: 36280-36288.
31. Leung KW, Cheng YK, Mak NK, Chan KK, Fan TP and Wong RN. Signaling pathway of ginsenoside- Rg1 leading to nitric oxide production in endothelial cells. FEBS Lett 2006; 580: 3211-3216.
32. Zhang W, Wojta J and Binder BR. Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Arterioscler Thromb 1994; 14: 1040-1046.
33. Lin SG, Zheng XL, Chen QY and Sun JJ. Effect of Panax notoginseng saponins on increased proliferation of cultured aortic smooth muscle cells stimulated by hypercholesterolemic serum. Zhongguo Yao Li Xue Bao 1993; 14: 314-316.
34. Helms S. Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 2004; 9: 259-274.
35. Jin YR, Yu JY, Lee JJ, You SH, Chung JH, Noh JY, Im JH, Han XH, Kim TJ, Shin KS, Wee JJ and Yun YP. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007; 100: 170-175.
36. Zhang C, Liu L, Yu Y, Chen B, Tang C and Li X. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 2012; 5: 1295-1298.
37. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA and Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
38. Calver A, Collier J, Moncada S and Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10: 1025-1031.
39. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R and Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459.
40. Kublickiene KR, Cockell AP, Nisell H and Poston L. Role of nitric oxide in the regulation of vascular tone in pressurized and perfused resistance myometrial arteries from term pregnant women. Am J Obstet Gynecol 1997; 177: 1263-1269.
41. Moncada S, Palmer RM and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
42. Closs EI, Simon A, Vekony N and Rotmann A. Plasma membrane transporters for arginine. J Nutr 2004; 134: 2752S-2759S; discussion 2765S-2767S.
43. Zharikov SI and Block ER. Characterization of L-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells. Biochim Biophys Acta 1998; 1369: 173-183.
44. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, Cohen JC, Rubin EM and Pennacchio LA. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010; 464: 409-412.
45. Holdt LM, Beutner F, Scholz M, Gielen S, Gabel G, Bergert H, Schuler G, Thiery J and Teupser D. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arteriscler Thromb Vasc Biol 2010; 30: 620-627.
46. Annilo T, Kepp K and Laan M. Natural antisense transcript of natriuretic peptide precursor A (NPPA): structural organization and modulation of NPPA expression. BMC Mol Biol 2009; 10: 81.